Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) – Pipeline Review, H2 2017’, provides in depth analysis on Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Oncology, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology and Ophthalmology under development targeting Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3SBio Inc

Io Therapeutics Inc

Phosphagenics Ltd

Sol-Gel Technologies Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview 7

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 12

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development 20

3SBio Inc 20

Io Therapeutics Inc 20

Phosphagenics Ltd 20

Sol-Gel Technologies Ltd 21

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles 22

(benzoyl peroxide + tretinoin) - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

(clindamycin phosphate + tretinoin) - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

(gemfibrozil + tretinoin) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

alitretinoin - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

IRX-5183 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

SBD-073 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

tamibarotene - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

TPX-6001 + tretinoin - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

tretinoin - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

tretinoin - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

vitamin A palmitate - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

vitamin A palmitate - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products 44

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products 46

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones 47

Featured News & Press Releases 47

Aug 31, 2017: Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress 47

Aug 21, 2017: Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML 47

Jul 21, 2017: Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients 48

Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris 49

Jun 23, 2017: Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients 50

May 18, 2017: Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients 51

May 08, 2017: Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARa Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference 52

May 04, 2017: Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer 53

May 01, 2017: Syros Participates in International Symposium to Support MDS Foundation’s Efforts to Raise Awareness of Novel Therapies in Development for MDS 54

Apr 18, 2017: Syros to Present on SY-1425, Its First-in-Class Selective RARa Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference 54

Apr 04, 2017: Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARa Agonist, for Genomically Defined AML and MDS Patients 55

Mar 01, 2017: Syros to Present New Data on SY-1425 at Upcoming AACR Annual Meeting 56

Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1425 57

Dec 10, 2016: Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RARa Agonist in Genomically Defined Subsets of Breast Cancer 59

Dec 05, 2016: Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARa Agonist for Genomically Defined Subsets of AML and MDS Patients 60

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by 3SBio Inc, H2 2017 20

Pipeline by Io Therapeutics Inc, H2 2017 20

Pipeline by Phosphagenics Ltd, H2 2017 21

Pipeline by Sol-Gel Technologies Ltd, H2 2017 21

Dormant Products, H2 2017 44

Dormant Products, H2 2017 (Contd..1), H2 2017 45

Discontinued Products, H2 2017 46

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports